buy narrow gap ret
extend runway pt
messag announc sever pipelin updat conjunct
equiti financ posit news includ first interim data pivot trial ret
inhibitor lung thyroid cancer indic compar efficaci
acceler regulatori timelin vs prior guidanc
avapritinib follow recent fda meet advanc phase
ii trial fop patient updat model reflect financ
improv pipelin outlook increas pt previous
interim efficaci data look competit rel
consist upsid thesi link interim result phase arrow dose
expans cohort recommend phase ii start dose mg qd
includ respons rate orr second-lin ret non-smal cell lung cancer
nsclc patient orr second-lin ret medullari thyroid cancer mtc
compar favor prior phase dose-escal orr data
ret-fus posit lung cancer ret nsclc present
ret-mut posit medullari thyroid cancer ret mtc present
ata link littl valu previous account stock
view context strong result wclc
similar patient think interim data seem indic two drug could
rather similar term efficaci orr ret nsclc
ret mtc
earlier nda submiss narrow potenti time gap
launch narrow guidanc potenti nda submiss nsclc
previous given earli enrol complet pivot second-lin ret
nsclc trial follow recent fda meet time potenti
nda submiss mtc remain expect pivot trial
enrol complet meanwhil recent guid potenti
nda submiss ret nsclc ye launch
updat regulatori guidanc avapritinib gastrointestin stromal tumor gist
system mastocytosi sm increment posit addit plan
nda file pdgfra gist announc plan
file potenti european approv within sm compani narrow
guidanc potenti nda file previous follow recent
meet regul spoke manag note file would
contain predominantli phase explor data advanc sm supplement phase
ii pathfind interim data patient dose qd dose indol
smolder sm yet includ estim repres potenti upsid
current valuat see takeaway recent kol call
inhibitor advanc phase ii studi announc
expect initi phase iia trial patient fibrodysplasia ossifican
progressiva fop base feedback clinic expert progress
on-going phase healthi volunt posit newsflow repres potenti upsid
current valuat current includ model
updat estim pt reflect new data compani guidanc
time regulatori event pt increas peak share
assumpt within ret nsclc mtc previous consider
similar efficaci vs potenti launch time shortli competitor
potenti front-lin use pend posit phase result ret
nsclc initi repres consider upsid valuat
page analyst certif import disclosur
updat potenti launch year avapritinib sm previous
consider updat guidanc increas peak market share previous
pend data updat ripretinib sm link probability-of-success
avapritinib gist increas previous base recent posit kol
comment receiv avapritinib approv base single-arm trial gist
inclus pdgfra patient file data new pt
page analyst certif import disclosur
valuat risk
valu per share previous use dcf base valuat
method valuat includ probability-adjust cash flow deriv compani
 pipelin includ avapritinib use discount rate termin growth
rate appli termin year post-assum gener entri lead pipelin candid
risk valuat includ regulatori commerci setback
potenti emerg new competitor lower product sale expect
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
